Charles River Laboratories International, Inc. (CRL) Receives Average Recommendation of “Buy” from Analysts

Charles River Laboratories International logoCharles River Laboratories International, Inc. (NYSE:CRL) has earned a consensus advice of “Buy” from the twelve brokerages which can be overlaying the agency, MarketBeat Ratings stories. Five badysts have rated the inventory with a maintain ranking, 5 have badigned a purchase ranking and one has issued a robust purchase ranking on the corporate. The common twelve-month goal worth amongst badysts which have lined the inventory within the final yr is $103.77.

CRL has been the subject of plenty of badysis badyst stories. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” ranking to a “hold” ranking in a badysis observe on Tuesday, July 25th. Robert W. Baird reiterated a “buy” ranking and set a $114.00 goal worth on shares of Charles River Laboratories International in a badysis report on Friday, September 1st. BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” ranking to a “buy” ranking in a badysis report on Monday, July 31st. Royal Bank Of Canada began protection on shares of Charles River Laboratories International in a badysis report on Tuesday, September 19th. They set a “sector perform” ranking and a $110.00 goal worth on the inventory. Finally, Credit Suisse Group reiterated a “neutral” ranking and set a $112.00 goal worth (up from $95.00) on shares of Charles River Laboratories International in a badysis report on Monday, October 16th.

In different Charles River Laboratories International information, insider David Ross Smith offered 2,552 shares of the agency’s inventory in a transaction that occurred on Monday, August 14th. The shares have been offered at a median worth of $67.10, for a complete transaction of $171,239.20. Following the completion of the transaction, the insider now owns 11,671 shares within the firm, valued at roughly $783,124.10. The transaction was disclosed in a doc filed with the SEC, which will be accessed via the SEC web site. Also, insider Davide Molho offered 6,165 shares of the agency’s inventory in a transaction that occurred on Thursday, October fifth. The inventory was offered at a median worth of $110.00, for a complete transaction of $678,150.00. The disclosure for this sale will be discovered right here. In the final 90 days, insiders have offered 18,699 shares of firm inventory valued at $1,892,393. Company insiders personal 2.20% of the corporate’s inventory.

A variety of institutional traders have lately added to or decreased their stakes in CRL. YorkBridge Wealth Partners LLC raised its holdings in Charles River Laboratories International by 445.5% through the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical badysis firm’s inventory price $118,00zero after buying a further 891 shares over the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Charles River Laboratories International by 12.7% through the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical badysis firm’s inventory price $181,00zero after buying a further 202 shares over the last quarter. Riverhead Capital Management LLC raised its holdings in Charles River Laboratories International by 14.7% through the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical badysis firm’s inventory price $195,00zero after buying a further 247 shares over the last quarter. Cambridge Advisors Inc. purchased a brand new place in Charles River Laboratories International through the 2nd quarter price roughly $202,00zero. Finally, Advisor Partners LLC purchased a brand new place in Charles River Laboratories International through the 2nd quarter price roughly $208,00zero. Hedge funds and different institutional traders personal 97.63% of the corporate’s inventory.

Shares of Charles River Laboratories International (CRL) opened at $117.75 on Friday. The firm has a present ratio of 1.74, a fast ratio of 1.49 and a debt-to-equity ratio of 1.16. The firm has a market cap of $5,604.19, a price-to-earnings ratio of 23.69, a P/E/G ratio of 1.89 and a beta of zero.94.

Charles River Laboratories International (NYSE:CRL) final posted its quarterly earnings outcomes on Wednesday, August ninth. The medical badysis firm reported $1.29 earnings per share for the quarter, beating badysts’ consensus estimates of $1.22 by $zero.07. Charles River Laboratories International had a internet margin of 10.13% and a return on fairness of 27.02%. The firm had income of $469.13 million for the quarter, in comparison with the consensus estimate of $458.25 million. During the identical interval final yr, the corporate posted $1.20 EPS. The agency’s quarterly income was up eight.1% in comparison with the identical quarter final yr. equities badysis badysts forecast that Charles River Laboratories International will submit 5.1 EPS for the present yr.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories International, Inc. (CRL) Receives Average Recommendation of “Buy” from Analysts” was posted by InventoryNewsOccasions and is the property of of InventoryNewsOccasions. If you’re studying this text on one other area, it was illegally copied and republished in violation of U.S. & worldwide copyright legal guidelines. The authorized model of this text will be accessed at https://stocknewstimes.com/2017/11/05/charles-river-laboratories-international-inc-crl-receives-average-recommendation-of-buy-from-badysts.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract badysis firm. The Company is engaged in laboratory animal medication and science (badysis mannequin applied sciences) and develop a portfolio of discovery and security evaluation companies, each good laboratory apply (GLP) and non-GLP, which helps its shoppers from goal identification via non-clinical improvement.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)




Receive News & Ratings for Charles River Laboratories International Inc. Daily – Enter your e-mail tackle beneath to obtain a concise day by day abstract of the newest information and badysts’ scores for Charles River Laboratories International Inc. and badociated firms with MarketBeat.com’s FREE day by day e-mail publication.


Source hyperlink

Leave a Reply